AC
ICPT

Aisling Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Aisling Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-137,519
Closed -$9.4M – 6
2013
Q4 		$9.4M Buy
+137,519
New +$7.95M 5.75% 4

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Aisling Capital's ICPT Position: Q1 2014 in Review

Aisling Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2014, closing a stake of 137,519 shares — an estimated $9.4M sold.

Aisling Capital first reported a position in ICPT in Q4 2013 and held it in 1 quarter. The position peaked at $9.4M in Q4 2013. 172 funds tracked by Wall St. Rank hold ICPT as of Q1 2014.

  • Aisling Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • Aisling Capital sold 137,519 Intercept Pharmaceuticals, Inc. shares in Q1 2014, an estimated $9.4M.
  • Aisling Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 1 quarter.
  • Aisling Capital's Intercept Pharmaceuticals, Inc. position peaked at $9.4M in Q4 2013.
  • 172 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2014.

Based on Aisling Capital's 13F filing for Q1 2014, filed 13 May 2014.